You are here

Article Text

Article menu

Download PDFPDF

Chest clinic
Basic Science for the Chest Physician
TB vaccine development: where are we and why is it so difficult?
  1. Morven E M Wilkie,
  2. Helen McShane
  1. The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford, UK
  1. Correspondence to Professor Helen McShane, The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK; helen.mcshane{at}ndm.ox.ac.uk

Abstract

The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either ‘boost’ a BCG primed immune system or replace BCG altogether is a key area for innovative research. Here, we discuss some of the issues encountered in the development of potential candidate vaccines and the future challenges.

  • Tuberculosis

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

https://doi.org/10.1136/thoraxjnl-2014-205202

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Linked Articles